SSA
KYTX icon

Schonfeld Strategic Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,154
Closed -$174K – 3070
2026
Q1 		$174K Sell
20,154
-8,718
-30% -$72.6K ﹤0.01% 1775
2025
Q4 		$271K Buy
+28,872
New +$214K ﹤0.01% 1608
2024
Q3 		– Sell
-61,303
Closed -$460K – 2487
2024
Q2 		$460K Buy
+61,303
New +$937K ﹤0.01% 1525

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Schonfeld Strategic Advisors's KYTX Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Kyverna Therapeutics (KYTX) in Q2 2026, closing a stake of 20,154 shares — an estimated $174K sold.

Schonfeld Strategic Advisors first reported a position in KYTX in Q2 2024 and held it in 3 quarters. The position peaked at $460K in Q2 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Kyverna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 20,154 Kyverna Therapeutics shares in Q2 2026, an estimated $174K.
  • Schonfeld Strategic Advisors first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Kyverna Therapeutics position peaked at $460K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.